Document:

EX-10.2

   

                                                                                                                        Exhibit 10.2                                

   

   

  FIRST AMENDMENT TO RESTATED LICENSE AGREEMENT

  Between

  ALS THERAPY DEVELOPMENT FOUNDATION, INC.

  And

  ANELIXIS THERAPEUTICS, INC.

   

  This First Amendment (“Amendment #1”) dated as of September 5, 2020 by and between ALS Therapy Development Foundation, Inc., d/b/a ALS Therapy Development Institute, Inc., a Massachusetts non-profit corporation (“ALSTDI”) and Anelixis Therapeutics, Inc., f/k/a Anelixis Pharmaceuticals, Inc., a Delaware corporation (“Company”) (each referred to as a “Party”, and together the “Parties”) hereby amends the Amended and Restated License Agreement between ALSTDI and the Company dated February 18, 2020, (the “Agreement”). Capitalized terms not otherwise defined in this Amendment #1 will have the same meanings as ascribed to such terms in the Agreement. In the event of any conflict between this Amendment #1 and the Agreement or the prior amendments, the terms contained in this Amendment #1 will prevail.

   

  R E C I T A L S

   

  WHEREAS, ALSTDI and the Company are parties to the Agreement, under which ALSTDI has licensed certain rights in patents and know-how to the Company; and

   

  WHEREAS, the Company also has financial obligations to ALSTDI in an amount of

  $904,805.45 pursuant to a separate service agreement (the “Master Services Agreement” dated May 20, 2015) for services through December 31, 2019 and the Company wishes to resolve these obligations in part by revision of certain financial terms in the Agreement as hereinafter set forth.

   

  NOW, THEREFORE, ALSTDI and Company hereby agree as follows:

   

  1.The Company shall pay ALSTDI two hundred and fifty thousand dollars ($250,000) contemporaneously with the execution of the Agreement.

   

  2.Article 4.1(a) of the Agreement is amended to read as follows.

   

  (a)Milestone Payments. Company shall notify ALSTDI within one hundred and twenty (120) days of the first achievement of any of the following milestones for the Licensed Product by Company or any of its Sublicensees. At the time of such notification, Company shall pay to ALSTDI the following one-time Milestone Payments for the first occurrence of each milestone event for the first Licensed Product:

   

   

   

  CONFIDENTIAL

  Page 1

  

   

                                                                                                                        Exhibit 10.2                                

  		
	Milestone Event
	Payment

	Dosing of first subject in first toxicity study in non- human primates
	$1,000,000

	Dosing of first patient in a Phase I Clinical Trial
	$1,000,000

	Dosing of first patient in Phase IIB Clinical Trial
	$ 200,000

	Dosing of first patient in a Phase III Clinical Trial
	$ 800,000

	First completion of a Phase III Clinical Trial with a positive clinical endpoint
	 
$1,000,000

	First Regulatory Approval in the US
	$1,000,000

	First Regulatory Approval in the European Union
	$1,000,000

	First Regulatory Approval in Asia
	$1,000,000

	First Commercial Sale in the Territory
	$1,000,000

   

  The parties acknowledge that the issuance to ALSTDI of 555,555 shares of the Company’s non-voting common stock pursuant to that certain Non-Voting Common Stock Purchase Agreement dated on or about June 1, 2017 fully satisfies the Company’s obligation to make that certain Milestone Payment for the dosing of the first subject in the first toxicity study in non-human primates pursuant to Section Error! Reference source not found. of the Agreement.

   

  Each Milestone Event may be achieved only once and each Milestone Payment shall be due only once following upon the first achievement of the corresponding Milestone Event. For the avoidance of doubt, in no event shall Company be obligated to pay to ALSTDI Milestone Payments exceeding $7,000,000.

   

  The first five Milestone Events above (the “Clinical Trial Milestones”) are intended to be successive; if any of the Clinical Trial Milestones is reached without achieving a preceding Clinical Trial Milestone, then the amount which would have been payable on achievement of the preceding Clinical Trial Milestone shall be payable upon achievement of the next successive Clinical Trial Milestone. For purposes of the above Milestone Events, the “completion” of a pre-clinical or clinical study means the date of the last examination or intervention of the last research subject for the purpose of data collection for the primary endpoint in that trial.

   

  In the event that the Company develops a second Licensed Product for disease indications different than the first Licensed Product, Company shall notify ALSTDI within ten (10) days of the first achievement of any of the following milestones for the second Licensed Product by Company or any of its Sublicensees. At the time of such notification,

   

  Company shall pay to ALSTDI the following one-time Milestone Payments for the first 

   

  CONFIDENTIAL

  Page 2

  

   

                                                                                                                        Exhibit 10.2                                

  occurrence of each milestone event for the second Licensed Product for a disease indication different than the first Licensed Product:

   

  		
	First completion of a Phase III Clinical Trial with a positive clinical endpoint
	 
$	500,000

	First Regulatory Approval in the US
	$	500,000

	First Regulatory Approval in the European Union
	$	500,000

	First Regulatory Approval in Asia
	$	500,000

	First Commercial Sale in the Territory
	$	500,000

   

  Notwithstanding the foregoing, ALSTDI may, in its sole discretion, defer receipt or acceptance of any Milestone Payment to any later date that it selects.

   

  3.     The payment by the Company of $250,000 and the above amendment to Article 4.1 (a) of the Agreement shall be deemed by the Parties to constitute full and complete payment of the aforementioned $904,805.45 owed by the Company to ALSTDI for services through December 31, 2019 pursuant to the Master Services Agreement.

   

  4.This Amendment #1, when fully executed and delivered together with the aforementioned

  $250,000 payment by the Company to ALSTDI, will be incorporated into the Agreement and the Agreement and this Amendment #1 will be deemed one and the same contract. Other than as specifically provided in revised Article 4.1(a), the terms and conditions of the Agreement are not modified by this Amendment # 1 and will remain in full force and effect.

   

  5.    This Amendment #1 constitutes the entire agreement between the parties with respect to the subject matter of Amendment #1 and supersedes all prior agreements or understandings between the parties relating to its subject matter, and may not be changed except by a further written agreement executed by the Parties.

   

  6.    In the event of any conflict between the Agreement and this Amendment #1, the terms contained in this Amendment #1 will prevail.

   

  7.   This Amendment #1 may be executed in counterparts, including by facsimile or by electronic scan copies, each of which counterparts, when so executed and delivered, shall be deemed to be an original, and all of which counterparts, taken together, shall constitute one and the same instrument.

   

  [SIGNATURES FOLLOW]

   

   

   

   

   

   

   

  CONFIDENTIAL

  Page 3

  

   

                                                                                                                        Exhibit 10.2                                

   

  IN WITNESS WHEREOF, the parties have caused this Amendment# 1 to the Amended and Restated License Agreement between ALSTDI and the Company dated February 18, 2020 to be executed by their duly authorized representatives as of the date first written above.

   

   

   

   

   

        ALS THERAPY DEVELOPMENT FOUNDATION, INC.

     By:	/s/ Alexander L. Cappello

     Name: Alexander L. Cappello

   Title: Authorized Director

   

          ANELIXIS THERAPEUTICS, INC.

    By:	/s/ Steven Perrin

    Name: Steven Perrin 

    Title: President

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

   

  CONFIDENTIAL

  Page 4EX-10.3

  Lonza                                                   

  CONFIDENTIAL     

  Exhibit 10.3

                                                                                                                              

   

   

  Certain identified information has been redacted from this exhibit because it is both (i) not material and (ii) a type that the registrant treats as private or confidential. Information that has been omitted has been identified in this document with a placeholder identified by the mark “[***].”

   

   

  LICENCE AGREEMENT

   

   

  between

   

   

  LONZA SALES AG

   

   

  and

   

   

  ANELIXIS THERAPEUTICS LLC

   

   

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

   

   

  INDEX

   

   

  ARTICLE    TITLE                                                                                                                       PAGE

   

  			
	1.
	DEFINITIONS AND INTERPRETATION
	3

	2.
	SUPPLY OF THE SYSTEM, CDACF VERSION 8.8 OR VERSION 8.8 SYSTEM AND SYSTEM KNOW-HOW
	7

	3.
	OWNERSHIP OF PROPERTY AND INTELLECTUAL PROPERTY
	8

	4.
	LICENCES
	8

	5.
	PAYMENTS
	10

	6
	ROYALTY PROCEDURES
	11

	7.
	LIABILITY AND WARRANTIES
	12

	8.
	CONFIDENTIALITY
	13

	9.
	INTELLECTUAL PROPERTY ENFORCEMENT
	14

	10.
	TERM AND TERMINATION
	15

	11.
	ASSIGNMENT
	16

	12.
	GOVERNING LAW AND DISPUTE RESOLUTION
	16

	13.
	FORCE MAJEURE	 
	17

	14.
	ILLEGALITY	   
	17

	15.
	MISCELLANEOUS	  
	17

	16.
	NOTICE	        
	18

   

  APPENDIX

   

  1[***]

  2[***]

  3[***]

  4[***]

   

   

   

  2

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  THIS AGREEMENT is made the BETWEEN the 11th day of September 2018

   

  BETWEEN

   

  LONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter referred to as "Lonza"), and

   

  ANELIXIS THERAPEUTICS LLC, of 300 Technology Square, 4th floor, Cambridge, MA, 02139, USA (hereinafter referred to as "Licensee")

   

  The Licensee and Lonza shall hereinafter jointly be referred to as the "Parties" and individually as the "Party".

   

  WHEREAS

   

  A  Lonza is the proprietor of the System and the CDACF Version 8.8 System and has the right to grant certain Intellectual Property Rights in relation thereto (all as hereinafter defined), and

   

  B.The Licensee wishes to take a licence under Intellectual Property Rights of which Lonza is the proprietor to commercially exploit the Product (as hereinafter defined) in the form hereunder.

   

   

  NOW THEREFORE the Parties hereby agree as follows:

   

   

  1.Definitions and Interpretation

   

  1.1In this Agreement the following words and phrases shall have the following meanings:

   

  1.1.1"Affiliate" means any company, corporation, limited liability company, partnership or other entity which directly or indirectly controls, is controlled by or is under common control, directly or indirectly, with the relevant Party to this Agreement. "Control" means the ownership of more than fifty percent (50%) of the issued share capital of the party in question or the legal power to direct or cause the direction of the general management and policies of the party in question. Such entity shall be deemed an Affiliate only so long as it satisfies the foregoing definition.

   

  1.1.2"CDACF Version 8.8 Base Powders" means the powders set out in Appendix

  2. 

   

  1.1.3"CDACF Version 8.8 Feeds" means the concentrated nutrient solutions used in order to maintain the growth and productivity of mammalian cells, as more fully set out in Appendix 3

   

  1.1.4"CDACF Version 8.8 Media" means the solutions of nutrients used in mammalian cell culture, as more fully set out in Appendix 3.

   

  1.1.5"CDACF Version 8.8 Know-How" means any Know-How specifically relating to the CDACF Version 8.8 Base Powders, CDACF Version 8.8 Feeds, CDACF Version 8.8 Media or the CDACF Version 8.8 Supplements used either in combination or individually, as set out in Appendix 4.

   

   

   

   

  3

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  1.1.6"CDACF Version 8.8 System" means the CDACF Version 8.8 Base Powders, CDACF Version 8.8 Feeds, CDACF Version 8.8 Media, CDACF Version 8.8 Know-How and the CDACF Version 8.8 Supplements used either in combination or individually.

   

  1.1.7"CDACF Version 8.8 Supplements" means the supplement solutions, as more fully set out in Appendix 3.

   

  1.1.8"Cell Lines" means those cell lines referred to in Clause 2.1.1.

   

  1.1.9"Competing Contract Manufacturer" shall mean any Third Party who, together with its affiliates, undertakes or performs more than fifty percent (50%) of their business as a third party manufacturer of monoclonal antibodies and/or therapeutic proteins or any product of a similar nature to which this Agreement relates.

   

  1.1.10"Confidential Information" means any Know-How and confidential information disclosed by one Party to the other in connection with this Agreement including for the avoidance of doubt the terms of this Agreement itself. In the case of Lonza, Confidential Information shall mean all information relating to the System and/or CDACF Version 8.8 System and any other materials, specifications or information which is provided and/or disclosed by Lonza, its Affiliates and their respective officers, employees, agents and advisors to the Licensee and its officers, employees, agents and advisors, whether directly or indirectly, including, without limitation, all agreements, research databases, trade secrets, Intellectual Property Rights, business and/ or commercial and/ or financial data (including data pertaining to Lonza's suppliers, agents, distributors and customers), specifications, technical designs, documents and drawings which are related to the System, the CDACF Version 8.8 System and/or Lonza's business.

   

  1.1.11"Effective Date" means the date first above written.

   

  1.1.12"Initiation" means, with respect to any clinical trial, the first date that a human subject is dosed in such clinical trial.

   

  1.1.13"Intellectual Property Rights" means all rights, title and interests, vested and/or arising out of any industrial or intellectual property, whether protected at common law or under statute, which includes (without limitation) any rights and interests in copyrights, designs, trademarks, service marks, trade-names, technology, business names, logos, commercial symbols, processes, developments, licenses, trade secrets, goodwill, drawings, computer software, formulae, technical information, research data, procedures, designs, Confidential Information and any other knowledge of any nature whatsoever throughout the world whether in existence today or which will come into existence in the future, and including all applications for patents, copyrights, trademarks, trade names, rights to apply and any amendments/modifications or renewals thereto; and all other intellectual property rights.

   

  1.1.14"Know-How" means any technical and other information, whether patented or unpatented, including, but without prejudice to the generality of the foregoing,

   

   

   

   

  4

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  ideas, concepts, trade secrets, know-how, inventions, discoveries, data, formulae, specifications, processes, procedures for experiments and tests and other protocols, results of experimentation and testing, fermentation and purification techniques and assay protocols.

   

  1.1.15"Net Sale" means all revenues recorded by or on behalf of Licensee or its Sublicensees for Product sold in the Territory. The permitted deductions booked on an accrual basis by Licensee and its Sublicensees under their respective accounting standards to calculate the recorded net sales from gross sales are as follows:

   

  (a)normal discounts actually granted, including without limitation, quantity, trade, cash and other discounts, rebates and charge-backs;

   

  (b)amounts refunded or credits allowed for Product or other goods returned or not accepted by customers;

   

  (c)packaging, transportation and prepaid insurance charges on shipments or deliveries to customers;

   

  (d)taxes, tariffs, customs duties, surcharges and other governmental charges actually incurred and paid by Licensee or its sublicensee hereunder in connection with the sale, exportation, importation or delivery of Product or other goods to customers.

   

  Subject to the qualification stated below, upon any sale or other disposal of Product by or on behalf of Licensee or its Sublicensee hereunder other than a bona fide arm's length transaction exclusively for money at market value or upon any use of the Product for purposes which do not result in a disposal of such Product in consideration of sales revenue customary in the country of use, such sale, other disposal or use shall be deemed to constitute a sale at the then current maximum selling price in the country in which such sale, other disposal or use occurs.

   

  Notwithstanding anything contained in this Agreement to the contrary, the supply of Product free of charge as commercial samples, or for use in preclinical studies, clinical trials or similar or related research studies, shall not be included in this provision.

   

  If the Product is sold as a combined product that consists of Product together with another therapeutically active ingredient or product for the same indication (a "Combination"), the Net Sales will be calculated by multiplying the Net Sales of the Combination (as defined using the Net Sales definition above) by the fraction, A/(A+B) where A is the weighted (by sales volume) average sale price of the Product in the relevant country, and B is the weighted average sale price (by sales volume) in that country of the product(s) containing the other component(s) in finished form. Regarding prices comprised in the weighted average price when sold separately referred to above, if these are available for different dosages from the dosages of Product and other components that are included in the Combination, then the Parties shall mutually agree on the appropriate proportional adjustment to such prices in calculating the royalty­ bearing Net Sales of the Combination. If the weighted average sale price cannot be determined for the Product or other component(s), the calculation of Net Sales for a Combination will be mutually agreed upon by the Parties based

   

   

   

   

  5

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  on the relative value contributed by each component, such agreement to be negotiated in good faith without unreasonable delay.

   

  1.1.16"Patent Rights (Lonza)" means the patents and applications, short particulars of which are set out in Appendix 1A hereto, and all patents and applications thereof of any kind throughout the world whether national or regional including but without prejudice to the generality of the foregoing, author certificates, inventor certificates, improvement patents, utility certificates and models and certificates of addition, and including any divisions, renewals, continuations, continuations in part, reissues, patent disclosures, improvements and extensions of reissue thereof.

   

  1.1.17"Patent Rights (Third Party)" means the patents and applications, short particulars of which are set out in Appendix 1B hereto, and to the extent granted to Lonza by the owners of the Patent Rights (Third Party), all patents and applications thereof of any kind throughout the world whether national or regional including but without prejudice to the generality of the foregoing, author certificates, inventor certificates, improvement patents, utility certificates and models and certificates of addition, and including any divisions, renewals, continuations, continuations in part, reissues, patent disclosures, improvements and extensions of reissue thereof.

   

  1.1.18"Product" means AT-1501 of which Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the System, or any formulation containing the same.

   

  1.1.19"Strategic Partner" means a party with whom Licensee has entered into a contractual relationship, to identify a therapeutic target, collaborate in the performance of research and development and/or commercialization of a Product or a product of which the Strategic Partner is the Proprietor. In no event may any entity that is primarily a Competing Contract Manufacturer be deemed a Strategic Partner for the purposes of this Agreement.

   

  1.1.20"Sublicensee" means any Third Party to which Licensee grants a sublicence of the rights granted to Licensee pursuant to this Agreement.

   

  1.1.21"System" means Lonza's glutamine synthetase gene expression system known as GS XceedTM consisting of the Cell Lines and the Vectors, and the System Know-How, whether used individually or in combination with each other. For the avoidance of doubt, any gene proprietary to Licensee inserted into the System for the purposes of producing Product does not form part of the System.

   

  1.1.22"System Know-How" means Know-How relating directly or indirectly to the System known to Lonza from time to time, of which Lonza is the proprietor.

   

  1.1.23"Territory" means world-wide.

   

  1.1.24"Third Party" means any individual or entity other than Lonza and Licensee

   

  1.1.25"Valid Claim" means a claim within the Patent Rights (Lonza) or the Patent Rights (Third Party) (including any re-issued and unexpired patents) which, but for the licence and other rights granted pursuant to Clauses 4.1 and 4.3 hereof, would be infringed by the manufacture, use, sale, offer for sale, exportation or

   

   

   

   

  6

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  importation of Product by Licensee or its Sublicensees and which also (a) has not been cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, and (b) has not been revoked, held invalid or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, and (c) has not been rendered unenforceable through disclaimer or otherwise, and (d) has not been disclaimed or otherwise dedicated to the public by Lonza, and (e) is not lost through an interference proceeding and any appeals therefrom.

   

  1.1.26"Vectors" means those vectors referred to in Clause 2.1.1.

   

  1.2The headings of this Agreement are inserted only for convenience and shall not affect the construction hereof.

   

  1.3Where appropriate words denoting a singular number only shall include the plural and vice versa.

   

  1.4References to the recitals, clauses and appendix shall be deemed to be a reference to the recitals, clauses and appendix to this Agreement and shall form an integral part of this Agreement.

   

  1.5References to any statute or statutory provision include a reference to the statute or statutory provision as from time to time amended, extended or re-enacted.

   

  1.6Reference in this Agreement to Lonza shall, unless repugnant to the subject or context thereof, include its Affiliates, successors and assigns.

   

   

  2.Supply of the System, CDACF Version 8.8 System and System Know-How

   

  2.1Unless previously supplied by Lonza under a separate agreement, Lonza shall, if requested by Licensee in writing, for regulatory purposes only and as approved by Lonza in writing, arrange for the supply ex-works Lonza's premises, Slough, Berkshire (lncoterms 2010) to Licensee of the following:

   

  2.1.1Vectors

  Approximately 20μg of vector pXC-17.4 Approximately 20μg of vector pXC-18.4

  Approximately 20μg of vector pH31K5 containing anti-insulin monoclonal

  antibody H31K5

   

  2.1.2Cell Lines

  Two 1.5 ml vials of the CHOK1SV-GS-KO cell line

   

  2.1.3System Know-How

  System Know-How contained as at the date hereinabove in (a) manuals of operating procedures for the System, (b) regulatory information in pdf format, and (c) Vector nucleotide sequences.

   

   

   

   

  7

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  2.2In the event that Licensee requires any additional quantities of the materials referred to in Clauses 2.1.1 and 2.1.2, and if Lonza at its sole discretion is willing to supply such

   

  additional materials, such supply shall be subject to the payment of an additional fee by Licensee to Lonza in accordance with Lonza's prices at the time.

   

  2.3In relation to the CDACF Version 8.8 System, Lonza shall following signature of this Agreement (a) provide Licensee with details of how to purchase the CDACF Version

  8.8 Base Powders and CDACF Version 8.8 Supplements to enable Licensee (and only Licensee) to make CDACF Version 8.8 Feeds and CDACF Version 8.8 Media and (b) supply Licensee with the CDACF Version 8.8 Know-How.

   

  2.4Licensee shall use the System only in the expression of Product by insertion of gene(s) coding for Product(s) into the System, and shall not use, cause the use of or permit to be used the System for any purpose not directly authorised by this Agreement.

   

  2.5The CDACF Version 8.8 System may only be used in conjunction with the System and may not be used in conjunction with any other gene expression system or for any other purpose whatsoever.

   

  2.6Any transportation of the System and/or CDACF Version 8.8 System by Lonza on behalf of Licensee shall be made at sole risk of the Licensee who shall be deemed to have full knowledge of the carrier's terms and conditions of carriage ("Carriage Terms"). The Licensee shall, as appropriate, observe, perform, and be subject to the Carriage Terms in relation to the transportation of the System and shall indemnify Lonza against all losses, expenses, demands, claims, actions, judgements, assessments, damages, liabilities, fines, penalties, costs and fees incurred by Lonza by reason of Licensee's failure to observe and perform the Carriage Terms.

   

   

  3.Ownership of Property and Intellectual Property

   

  3.1It is hereby acknowledged and agreed that as between the Parties any and all property and Intellectual Property Rights in the System and System Know-How Is vested in Lonza. Similarly it is hereby acknowledged as between the Parties any and all Intellectual Property Rights in the Product and any gene proprietary to Licensee, or any of its licensors or sublicensees, inserted into the System for the purpose of producing Product, is vested in Licensee, or its applicable licensors and sublicensees.

   

  3.2The provisions of this Clause 3 shall survive termination of this Agreement.

   

   

  4.Licences

   

  4.1Lonza hereby grants to Licensee on the Effective Date:

   

  (a)a world-wide non-exclusive licence under the System Know-How, CDACF Version 8.8 Know-How, and the Patent Rights (Lonza) (with the right to sublicence, subject to Clause 4.3 below);

   

  (b)a world-wide non-exclusive sublicence under the Patent Rights (Third Party) (with the right to sublicense, subject to Clause 4.3 below);

   

   

   

   

  8

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  in each case (a) and (b) to use, develop, manufacture, market, sell, offer for sale, distribute, import and export Product in the Territory ("Commercial Activities").

   

  4.2Save as expressly provided by Clause 2.4 above, the Licensee hereby undertakes not to make any modifications or adaptations to the System and the CDACF Version 8.8 System during the subsistence of this Agreement. For the avoidance of doubt, Licensee is not prevented from adding any materials to the System.

   

  4.3Subject to the provisions of this Clause 4.3, Licensee shall be entitled to grant a sublicence to the rights granted by Clause 4.1 to any one or more Third Parties for the purposes of any such Third Party producing Product for Licensee provided always:

   

  4.3.1Licensee shall ensure such sublicensee's use of the System the CDACF Version 8.8 System, Lonza's Intellectual Property Rights and the Product is undertaken solely for undertaking Commercial Activities, for or on behalf of Licensee; and

   

  4.3.2The Sublicensee shall not, by virtue of this Agreement, be granted any right or licence, either express or implied, under any patent or proprietary right vested in Lonza or otherwise, to use the System, the CDACF Version 8.8 System, Lonza's Intellectual Property Rights or the Product other than for undertaking Commercial Activities for or on behalf of Licensee and Licensee agrees to ensure that such Sublicensee shall not assign, transfer, further sublicense or otherwise make over the benefit or the burden of the rights granted to it pursuant to this Agreement; and

   

  4.3.3Any sublicence granted shall be granted expressly subject to the terms of this Agreement, and it shall be Licensee's responsibility to ensure the strict adherence by Sublicensee hereunder to the terms and conditions of this Agreement; and

   

  4.3.4Prior to the grant of any sublicence pursuant to this Clause 4 Licensee shall obtain the written consent of Lonza (such consent not to be unreasonably withheld, conditioned or delayed), to the grant of such sublicence. It is agreed between the Parties that Lonza shall be considered to be reasonably withholding its consent if it holds commercial concerns as to protection of its Intellectual Property Rights and confidentiality should Lonza's Intellectual Property Rights be licensed to the proposed Sublicensee; and

   

  4.3.5Licensee shall not sublicense the rights sublicensed to it under the Precision patents listed in Appendix 1B to Cellectis S.A. or any of its affiliates or its or their successors with affiliate meaning for the purposes of this Clause 4.3.5 any entity controlling, controlled by, or under common control with Cellectis S.A.

   

  4.4If, on a country-by-country basis, any granted patents that form part of the Patent Rights (Lonza) or Patent Rights (Third Party) (including any re-issued patents and unexpired patents), subsequently expire or no longer contain a Valid Claim such Patent Rights shall automatically fall outside the scope of this Agreement and the provisions of Clauses 4.1 to 4.3 shall only apply, with respect to granted patents, to those granted patents which contain a Valid Claim and form part of the Patents Rights (Lonza) or Patent Rights (Third Party) for as long as those granted patents remain in force.

   

  4.5Notwithstanding clause 4.4, on a country-by-country basis, where no Valid Claim remains in force, the provisions of Clauses 4.1 to 4.3 shall only apply for as long as the System Know-How and CDACF Version 8.8 Know-How (as appropriate) remain secret and substantial.

   

   

   

   

  9

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  4.6No licence is granted save as expressly provided herein and no licence in addition thereto shall be deemed to have arisen or be implied by way of estoppel or otherwise.

   

   

  5.Payments

   

  5.1In consideration of the licence granted to Licensee pursuant to Clause 4.1 above, and in consideration for the right to sublicense the rights granted by Clause 4.1 pursuant to Clause 4.3, Licensee shall pay Lonza as follows, subject to the adjustment as set forth in Clause 5.2:

   

  5.1.1in respect of Product manufactured by Lonza, a royalty of zero point eight five percent (0.85%) of Net Sales;

   

  5.1.2where Licensee or Licensee's Strategic Partner manufactures Product (whether for clinical or commercial purposes):

   

  5.1.2.1a payment of Swiss Francs one hundred thousand (CHF 100,000) due annually during the course of this Agreement, and being first payable upon Initiation of phase II clinical trials for Product and thereafter on each anniversary of such date; and

   

  5.1.2.2a royalty of one percent (1%) of Net Sales of Product.

   

  5.1.3where any party other than Lonza, Licensee or Licensee's Strategic Partner manufactures Product (whether for clinical or commercial purposes:

   

  5.1.3.1a payment of Swiss Francs four hundred thousand (CHF 400,000) per sublicence due annually during the course of such sublicence (irrespective as to the years of manufacture), and being first payable on the commencement date of the relevant sublicence; and

   

  5.1.3.2a royalty of one point seven five percent (1.75%) of Net Sales of Product.

   

  5.2If, on a country-by-country basis, the manufacture and/or sale of the Product are not protected by a Valid Claim (either because no patent or application was ever filed for such territory or the patent or application is no longer of effect) then in respect of sales in such countries:

   

  (a)the royalties referred to in 5.1.1, 5.1.2.2 and 5.1.3.2 shall be due only in respect of the System Know-How;

   

  (b)the royalties referred to in 5.1.1 and 5.1.2.2 shall be at the rate of zero point four two five per cent (0.425%) and zero point five per cent (0.5%) respectively of the Net Sales;

   

  (c)the royalties referred to in 5.1.3.2 shall be at the rate of zero point eight seven five per cent (0.875%) of the Net Sales.

   

  5.3For the avoidance of doubt the licence to use the CDACF Version 8.8 System is given in consideration of the obligations incumbent upon the Licensee under the terms of this Agreement but is otherwise royalty-free.

   

   

   

   

  10

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  6.Royalty Procedures

   

  6.1Licensee shall, and shall ensure that its Sublicensees shall, keep true and accurate records and books of account containing all data necessary for the calculation of royalties payable to Lonza. Such records and books of account shall, upon reasonable notice having been given by Lonza (which in no event shall be less than thirty (30) days prior notice), be open at all reasonable times during regular business hours for inspection by independent auditors selected by Lonza and reasonably acceptable to Licensee. Such independent auditors shall agree to maintain the confidentiality of the information and materials disclosed during the audit. Any such audit shall be conducted in a manner that does not interfere unreasonably with the operations of Licensee's business. Lonza may perform an audit once each calendar year. Each audit shall begin upon the date specified by Lonza and shall be completed as soon as reasonably practicable. Lonza shall pay the costs of the independent auditors conducting such audit, unless the results of the audit reveal an underpayment of 5% or more by Licensee, in which case, Licensee shall pay the reasonable costs of the independent auditors. If an audit concludes that an overpayment or underpayment has occurred during the audited period, such payment shall be remitted by the Party responsible for such payment to the other Party within thirty (30) days after the date such auditor's written report identifying the overpayment or underpayment is delivered to the Party responsible for such payment.

   

  6.2Licensee shall prepare a statement in respect of each calendar quarter which shall show for the immediately preceding quarter details of the sales of Product on a country by country basis and the royalty due and payable to Lonza thereon.

   

  Such statement shall be submitted to Lonza within thirty (30) days after the end of the calendar quarter to which it relates, together with a remittance for the royalties due to Lonza to which Lonza shall issue a receipted invoice in return.

   

  6.3All sums due under this Agreement:

   

  6.3.1shall be paid in Swiss Francs to Lonza.

   

  6.3.2are exclusive of any Value Added Tax or of any other applicable taxes, levies, imposts, duties and fees of whatever nature imposed by or under the authority of any government or public authority, and shall be paid by Licensee (other than taxes on Lonza's income). The parties agree to co-operate in all respects reasonably necessary to take advantage of such double taxation treaties as may be available.

   

  6.4To the extent that Licensee reports Net Sales otherwise than in Swiss Francs then royalty payments due to Lonza shall be first calculated in the local currency in which Net Sales are reported and then shall be converted to a Swiss Franc value first published in the Financial Times on the first business day after the relevant quarterly reporting period.

   

  6.5Where Lonza does not receive payment of any sum by the due date, interest shall accrue thereafter on the sum due and owing to Lonza at the rate of four percent (4%) per annum over the base rate from time to time of National Westminster Bank plc,

   

   

   

   

  11

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  interest to accrue on a day-to-day basis without prejudice to Lonza's right to receive payment on the due date.

   

   

  7.Liability and Warranties

   

  7.1Subject to Clause 7.2, Lonza gives no representation or warranty that the Patent Rights (Lonza) or Patent Rights (Third Party) which are patent applications will be granted or if granted will be valid nor that the exercise of the rights granted to Licensee hereunder will not infringe other patent rights or intellectual property rights vested in Lonza or any Third Party.

   

  7.2Lonza warrants that the patents included in the Patent Rights (Lonza) are the only patents that must be licensed from Lonza and/or its Affiliates in order to operate the System.

   

  7.3The Licensee hereby acknowledges that in order to exploit the rights granted herein the Licensee may require licences under Lonza patent rights (other than those herein licensed) or under Third Party patent rights (including those vested in Affiliates of Lonza) that may be infringed by the use by the Licensee of the rights licensed herein and it is hereby agreed that it shall be the Licensee's responsibility to satisfy itself as to the need for such licences and if necessary to obtain such licences; provided that any such patent rights vested in Lonza or its Affiliates which are necessary for Licensee and its Sublicensees to operate the System as permitted by the terms of this Agreement shall be automatically included within the Intellectual Property Rights licensed to Licensee hereunder.

   

  7.4Each Party ("Indemnifying Party") shall indemnify and hold harmless the other Party and its Affiliates, and their respective officers, employees and agents (each an "Indemnified Party") at all times in respect of any and all losses, damages, costs and expenses (collectively "Losses") suttered or incurred as a result of any contractual, tortious or other claims or proceedings by Third Parties (collectively "Third Party Claims") against Indemnified Party arising out of the Indemnifying Party's breach of this Agreement, including breach of representations and warranties, violation of applicable law, negligence or wilful misconduct; provided that with respect to any Third Party Claim for which each Party is entitled hereunder to seek indemnification from the other Party, each Party as the Indemnifying Party shall indemnify the other Party for its Losses only to the extent of the Indemnifying Party's relative responsibility for the facts underlying the Third Party Claim .

   

  7.5With respect to product liability claims or proceedings, the following shall apply: (a) except to the extent provided in (b) below, Licensee shall indemnify and hold harmless Lonza, its Affiliates and their respective officers, employees and agents at all times in respect of any and all losses, damages, costs and expenses suffered or incurred as a result of any tortious claims or proceedings of death or bodily injury relating to the Product, and (b) Lonza shall indemnify and hold harmless Licensee, its Affiliates and their respective officers, employees and agents at all times in respect of any and all losses, damages, costs and expenses suffered or incurred as a result of any tortious claims or proceedings of death or bodily injury relating to the Product to the extent such claims or proceedings result from defects in the Cell Lines and Vectors, or from Lonza's breach of this Agreement.

   

   

   

   

  12

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  7.6Any condition or warranty other than those relating to title which might otherwise be implied or incorporated within this Agreement by reason of statute or common law or otherwise is hereby expressly excluded.

   

  7.7EXCEPT FOR EITHER PARTY'S BREACH OF CLAUSE 8 HEREOF IN NO EVENT SHALL EITHER PARTY OR THEIR RESPECTIVE AFFILIATES BE LIABLE TO THE OTHER PARTY, THEIR AFFILIATES AND THEIR RESPECTIVE OFFICERS, EMPLOYEES AND AGENTS WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT WHETHER IN CONTRACT IN TORT IN NEGLIGENCE OR FOR BREACH OF STATUTORY DUTY OR OTHERWISE FOR LOSS OF PROFITS, SPECIAL,   INDIRECT,   INCIDENTAL,   PUNITIVE,   EXEMPLARY   OR

  CONSEQUENTIAL DAMAGES. Nothing in this Agreement shall exclude or limit the liability of either Party for fraud or for death or personal injury caused by its negligence or for any other liability that may not be limited or excluded as a matter of law.

   

  7.8The terms of this Clause 7 shall survive expiration or termination of this Agreement for whatever reason.

   

   

  8.Confidentiality

   

  8.1Licensee expressly acknowledges that Confidential Information disclosed by Lonza pursuant to this Agreement is supplied in circumstances imparting an obligation of confidence and Licensee shall keep such Confidential Information secure, secret and confidential and undertakes to respect Lonza's proprietary rights therein and to use the same for the sole purpose of this Agreement and not during the period of this Agreement or at any time for any reason whatsoever to disclose, cause or permit to be disclosed such Confidential Information to any Third Party other than its Sublicensee hereunder for use in accordance with the terms of this Agreement. Licensee shall procure that only its employees and employees of its Sublicensee hereunder shall have access to Confidential Information and then only on a need to know basis and that all such employees shall be informed of their secret and confidential nature and shall be subject to the same obligations as Licensee and its Sublicensee hereunder pursuant to this Clause 8.1.

   

  8.2Lonza expressly acknowledges and undertakes that any Confidential Information disclosed by the Licensee to Lonza pursuant to this Agreement is disclosed in circumstances imparting an obligation of confidence and Lonza shall keep such Licensee's Confidential Information secure, secret and confidential and undertakes to respect Licensee's proprietary rights therein and to use the same for the sole purpose of this Agreement and not during the period of this Agreement or at any time for any reason whatsoever disclose and/or cause and/or permit to be disclosed such Licensee's Confidential Information to any Third Party.

   

  8.3Each Party will restrict the disclosure of Confidential Information to such officers, employees, professional advisers, finance-providers, and consultants of itself and its Affiliates ("Representatives") who have been informed of the confidential nature of the Confidential Information and who have a need to know such Confidential Information for the purpose of this Agreement. Prior to disclosure to such persons, the Party in receipt of the Confidential Information shall bind its and its Affiliates' Representatives to confidentiality and non-use obligations no less stringent than those set forth herein. The receiving Party shall notify the disclosing Party as promptly as practicable of any unauthorized use or disclosure of the Confidential Information.

   

   

   

   

  13

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  8.4The obligations of confidence referred to in this Clause 8 shall not extend to any information which the receiving Party demonstrates:

   

  8.4.1is or shall become generally available to the public otherwise than by reason of a breach by the recipient Party of such information of the provisions of this Clause 8;

   

  8.4.2is known to the recipient Party of such information and is at its free disposal prior to its receipt from the other;

   

  8.4.3is subsequently disclosed to the recipient Party without obligations of confidence by a Third Party owing no such obligation of confidentiality to the disclosing Party; or

   

  8.4.4can be demonstrated by competent written evidence as having been independently developed by the recipient of the information in question without access to or use or knowledge of the information of the disclosing Party.

   

  8.5Notwithstanding the foregoing it is acknowledged between the Parties that Lonza or Licensee may be required to disclose Confidential Information to a government agency for the purpose of any statutory, regulatory or similar legislative requirement applicable to the production of Product, or to a court of law or to meet the requirements of any Stock Exchange to which the Parties may be subject. In such circumstances the disclosing Party will inform the other Party prior to disclosure being made as to the nature of the required disclosure, shall only make the disclosure to the extent legally required and shall seek to impose obligations of secrecy wherever possible. Notwithstanding such disclosure such Confidential Information shall otherwise remain subject to this Clause 8.

   

  8.6Each Party hereto expressly agrees that any breach or threatened breach of the undertakings of confidentiality provided hereunder by a Party may cause irreparable harm to the other Party ("Non-Breaching Party") and that money damages may not provide a sufficient remedy to the Non-Breaching Party for any breach or threatened breach. In the event of any breach and/or threatened breach, then in addition to all other remedies available at law or in equity, the Non-Breaching Party shall be entitled to seek injunctive relief and any other relief deemed appropriate by the Non-Breaching Party.

   

  8.7The obligations of both Parties under this Clause 8 shall survive the expiration or termination of this Agreement for whatever reason.

   

   

  9.Intellectual Property Enforcement

   

  9.1Lonza hereby undertakes and agrees that at its own cost and expense it will:

   

  9.1.1prosecute or procure prosecution of such of the Patent Rights (Lonza) which are patent applications diligently so as to secure the best commercial advantage obtainable, as determined by Lonza in its commercially reasonable discretion, and will pursue, as determined by Lonza in its commercially reasonable discretion, all necessary actions against any Third Party that Lonza reasonably believes is infringing, misappropriating or violating any Lonza Intellectual Property Rights; and

   

   

   

   

  14

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  9.1.2pay or procure payment of all renewal fees in respect of the Patent Rights (Lonza) to ensure they are valid and subsisting for the full term thereof and in particular will procure such renewal of the registrations thereof as may be necessary from time to time so far as it is reasonable to do so with particular reference to commercial considerations.

   

  9.2Licensee shall promptly notify Lonza in writing of any infringement or improper or unlawful use of or of any challenge to the validity of the Patent Rights (Lonza) and/or Know-How. Lonza undertakes and agrees to take all such steps and proceedings and to do all other acts and things as may in Lonza's sole discretion be necessary to restrain any such infringement or improper or unlawful use or to defend such challenge to validity and Licensee shall permit Lonza to have the sole conduct of any such steps and proceedings including the right to settle them whether or not Licensee is a party to them. Licensee shall have the right at its own cost and for its own benefit to initiate, prosecute and control the enforcement of the Patent Rights (Lonza) against infringement by a Third Party in the Territory if all of the following conditions are fulfilled

  (a) the product manufactured through the infringing activity is a competing product to the Product, (b) Lonza has not granted rights to Third Parties which prevent Lonza from granting such a right to enforce to Licensee, and (c) Lonza does not initiate proceedings within sixty (60) days of being requested to do so by Licensee.

   

   

  10.Term and Termination

   

  10.1Unless terminated earlier in accordance with the provisions of this Clause 10 or Clause 14, this Agreement shall continue in force in each country of the world, until (i) expiry of the last Valid Claim or (ii) ten (10) years from the First Commercial Sale of the Product provided that the System Know-How and/or CDACF Version 8.8 Know-How is identified and remains secret and substantial, whichever is later.

   

  10.2Licensee may terminate this Agreement by giving sixty (60) days' notice in writing to Lonza.

   

  10.3Either Lonza or Licensee may terminate this Agreement forthwith by notice in writing to the other upon the occurrence of any of the following events:

   

  10.3.1if the other commits a breach of this Agreement which in the case of a breach capable of remedy shall not have been remedied within thirty (30) days of the receipt by the other of a notice identifying the breach and requiring its remedy

   

  10.3.2if the other is unable to pay its debts or enters into compulsory or voluntary liquidation (other than for the purpose of effecting a reconstruction or amalgamation in such manner that the company resulting from such reconstruction or amalgamation if a different legal entity shall agree to be bound by and assume the obligations of the relevant Party under this Agreement) or compounds with or convenes a meeting of its creditors or has a receiver or administrator appointed over all or any part of its assets or takes or suffers any similar action in consequence of a debt, or ceases for any reason to carry on business.

   

  10.4If at any time during this Agreement Licensee knowingly, directly or indirectly, opposes or assists any Third Party to oppose the grant of letters patent or any patent application within any of the Patent Rights (Lonza) or disputes or knowingly, directly or indirectly, assists any Third Party to dispute the validity of any patent within any of the Patent

   

   

   

   

  15

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  Rights (Lonza) or any of the claims thereof Lonza shall be entitled at any time thereafter to terminate all or any of the licences granted hereunder forthwith by notice to Licensee.

   

  10.5If this Agreement expires or is terminated for any reason any and all licences granted hereunder shall terminate with effect from the date of termination and Licensee shall destroy all Vectors, Cell Lines and Product and all Confidential Information which is provided by Lonza (including all Know-How, all System Know-How and all CDACF Version 8.8 System Know-How) forthwith and shall certify such destruction immediately thereafter in writing to Lonza provided however that the Licensee and Sublicensees shall have the right to sell or otherwise dispose of all Product then on hand, subject to the payment of royalties and the other terms of this Agreement.

   

  10.6Termination for whatever reason or expiration of this Agreement shall not affect the accrued rights of the Parties arising in any way out of this Agreement as at the date of termination. The right to recover damages against the other and all provisions which are expressed to survive this Agreement shall remain in full force and effect.

   

   

  11.Assignment

   

  11.1Save as expressly provided by Clause 4, neither Party shall be entitled to assign, transfer, charge or in any way make over the benefit and/or the burden of this Agreement without the prior written consent of the other which consent shall not be unreasonably withheld or delayed, save that Lonza shall be entitled without the prior written consent of the Licensee to assign, transfer, charge, sub-contract, deal with or in any other manner make over the benefit and/or burden of this Agreement (i) to an Affiliate or (ii) to any joint venture company of which Lonza is the beneficial owner of at least fifty percent (50%) of the issued share capital thereof or (iii) to any company with which Lonza may merge or (iv) to any company to which Lonza may transfer its assets and undertaking.

   

  11.2This Agreement shall be binding upon the successors and assigns of the parties and the name of a Party appearing herein shall be deemed to include the names of its successors and assigns provided always that nothing herein shall permit any assignment by either Party except as expressly provided herein.

   

   

  12.Governing Law and Dispute Resolution

   

  12.1The validity, construction and performance of this Agreement shall be governed by English law to which the Parties submit.

   

  12.2Subject to Clause 12.3, the Courts of England and Wales shall have exclusive jurisdiction in relation to this Agreement provided that the Parties shall have the right to proceed to a suitable jurisdiction for the purpose of enforcing a judgment, award, or order (including without limitation seeking specific performance) and injunctive reliefs.

   

  12.3Any dispute arising between the Parties under this Agreement may upon the mutual agreement of the Parties be referred to and finally settled by arbitration under the Rules of Arbitration of the International Chamber of Commerce by a single arbitrator knowledgeable in biopharmaceutical research and development related matters and familiar with the biopharmaceutical industry, appointed in accordance with the said Rules. The place of arbitration shall be London, England and the arbitration shall be

   

   

   

   

  16

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  conducted in the English language. The arbitrator's award shall be final and binding. The Parties covenant and agree that they will participate in the arbitration in good faith and that they will share equally the costs of the arbitration, except as otherwise provided herein. Any Party refusing to comply with an order of the arbitrator will be liable for costs and expenses, including attorney's fees, incurred by the other Party in enforcing an award.

   

   

  13.Force Majeure

   

  Neither Party shall be in breach of this Agreement if there is any total or partial failure of performance by it of its duties and obligations under this Agreement occasioned by any act of God (including without limitation, fire), act of government or state, war, civil commotion, insurrection, embargo, epidemic, terrorism or earthquake, prevention from or hindrance in obtaining any raw materials, energy or other supplies, labour disputes of whatever nature and any other reason beyond the control of either Party. If either Party is unable to perform its duties and obligations under this Agreement as a direct result of the effect of one of the reasons set out in this Clause 13 such Party shall give written notice to the other of such inability stating the reason in question. The operation of this Agreement shall be suspended during the period (and only during the period) in which the reason continues. Forthwith upon the reason ceasing to exist the Party relying upon it shall give written notice to the other of this fact. If the reason continues for a period of more than ninety (90) days and substantially affects the commercial basis of this Agreement the Party not claiming under this Clause 13 shall have the right to terminate this Agreement by giving written notice of such termination to the other Party.

   

   

  14.Illegality

   

  14.1If any provision or term of this Agreement or any part thereof shall become or be declared illegal, invalid or unenforceable for any reason whatsoever including but without limitation by reason of the provisions of any legislation or other provisions having the force of law or by reason of any decision of any Court or other body or authority having jurisdiction over the parties hereto or this Agreement including the EC Commission or the European Court of Justice:

   

  (i)such provision shall, so far as it is illegal, invalid or unenforceable, be given no effect by the Parties and shall be deemed not to be included in this Agreement;

   

  (ii)the other provisions of this Agreement shall be binding on the Parties as if such provision was not included therein; and

   

  (iii)the Parties agree to negotiate in good faith to amend such provision to the extent possible for incorporation herein in such reasonable manner as most closely achieves the intention of the Parties without rendering such provision invalid or unenforceable.

   

   

  15.Miscellaneous

   

  15.1This Agreement embodies and sets forth the entire agreement and understanding of the parties and supersedes all prior oral and written agreements, representations, misrepresentations (where innocently or negligently made), understandings or

   

   

   

   

  17

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  arrangements relating to the subject matter of this Agreement ("Understandings"). Neither Party shall be entitled to rely on any Understandings which are not expressly set forth in this Agreement.

   

  15.2This Agreement shall not be amended, modified, varied or supplemented except in writing signed by duly authorised representatives of the Parties.

   

  15.3No failure or delay on the part of either Party hereto to exercise any right or remedy under this Agreement shall be construed or operated as a waiver thereof nor shall any single or partial exercise of any right or remedy under this Agreement preclude the exercise of any other right or remedy or preclude the further exercise of such right or remedy as the case may be. The rights and remedies provided in this Agreement are cumulative and are not exclusive of any rights or remedies provided by law.

   

  15.4Except as required by law, the text of any press release or other communication to be published by or in the media whether of a scientific nature or otherwise and concerning this Agreement shall require the prior written approval of Lonza and Licensee.

   

  15.5Each of the Parties shall be responsible for its respective legal and other costs incurred in relation to the preparation of this Agreement.

   

  15.6The Parties do not intend that any term hereof should be enforceable by virtue of the Contracts (Rights of Third Parties) Act 1999, or by any other statute or common-law principle, by any person who is not a party to this Agreement.

   

   

  16.Notice

   

  16.1Any notice or other document to be given under this Agreement shall be in writing and shall be deemed to have been duly given if left at or sent by registered post or by a reputable overnight courier to a Party or delivered ,n person to a Party at the address set out below for such Party or such other address as the Party may from time to time designate by written notice to the other(s):

   

  Address of Lonza

  Lonza Sales AG, Muenchensteinerstrasse 38 CH-4402, Basel, Switzerland

   

  With a copy to: Lonza Biologics Plc	

          [***]

          E-mail: [***]

          Attn: [***]

        

   

  Address of Licensee

  ANELIXIS THERAPEUTICS LLC

  300 Technology Square, 4th floor, Cambridge, MA 02139

  Email: [***]

  Attn: [***]

   

  16.2All such notices and documents shall be in the English language. Any such notice or other document shall be deemed to have been received by the addressee seven (7) working days following the date of dispatch of the notice or other document by post or, where the notice or other document is sent by hand, at the time of such delivery. To prove the giving of a notice or other document it shall be sufficient to show that it was dispatched.

   

   

   

   

  18

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  AS WITNESS the hands of the duly authorised representatives of the parties hereto

   

   

  Signed for and on behalf of              

  LONZA SALES AG

  /s/ Bart A. M. van Aarnhem

  Senior Legal Counsel

   

  Signed for and on behalf of 

  LONZA SALES AG

  /s/ Jacov Wirtz

  Assoc. General Counsel

   

   

  Signed for and on behalf of	 

  ANELIXIS THERAPEUTICS LLC

  /s/ Steve Perrin

  CEO

   

   

   

   

   

   

   

   

   

  19

  

   

  Lonza                                                   

  CONFIDENTIAL                                                                                                                                                                             

  Exhibit 10.3

  APPENDIX 1A

   

  [***]

   

   

   

  20

  

   

  Lonza

  CONFIDENTIAL

  Exhibit 10.3

  APPENDIX 1B

   

  [***]

   

   

   

   

  21

  

   

  Lonza

  CONFIDENTIAL

  Exhibit 10.3

  APPENDIX 2

   

  [***]

   

   

   

   

  22

  

   

  Lonza

  CONFIDENTIAL

  Exhibit 10.3

  APPENDIX 3

   

   

  [***]

   

   

   

   

  23

  

   

  Lonza

  CONFIDENTIAL

  Exhibit 10.3

  APPENDIX 4

   

  [***]

   

   

   

   

  24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]